Nivolumab-induced large-duct cholangiopathy treated with ursodeoxycholic acid and tocilizumab.
Sign Up to like & getrecommendations! Published in 2019 at "Immunotherapy"
DOI: 10.2217/imt-2019-0121
Abstract: Immune checkpoint inhibitor therapy has become a cornerstone in the management of many oncologic diseases. Although it is well tolerated in most patients, a wide spectrum of adverse events has been described as a result… read more here.
Keywords: acid tocilizumab; cholangiopathy; ursodeoxycholic acid; nivolumab induced ... See more keywords